New drug aims to ease heavy periods caused by fibroids
NCT ID NCT07378098
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether the experimental drug KLH-2109 can reduce heavy menstrual bleeding in people with uterine fibroids. About 254 participants will take either KLH-2109 or a standard treatment for 24 weeks, tracking their bleeding and visiting the clinic for safety checks. The main goal is to see if KLH-2109 lowers bleeding enough to improve quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KLH-2109 (a drug taken as a pill)
- What this could lead to
- If successful, this could offer a new non-surgical option to reduce heavy bleeding in people with uterine fibroids.
- What could go wrong
- This is still an early Phase 3 trial with 254 participants. The drug may not prove more effective than existing treatments, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENORRHAGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a reusable device match the standard for uterine biopsy?
- Can watching videos before surgery calm nerves?
- A drug that may curb bleeding during fibroid surgery faces its first big test
- Could a common muscle relaxant cut narcotic use after hysterectomy?
- Vitamin cocktail may shrink fibroids, reduce surgery need
- Stiffness check could boost fibroid treatment success